<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>274(5)</volume><submitter>Besse M</submitter><funding>Universitätsmedizin Göttingen</funding><funding>Georg-August-Universität Göttingen</funding><pubmed_abstract>Electroconvulsive therapy (ECT) is an effective, safe, and mostly well-tolerated treatment for patients with severe or difficult to treat depression or psychotic disorders. However, a relevant number of patients experience subjective and/or objective cognitive side-effects. The mechanism of these transient deficits is not yet clear. Thus, our study prospectively investigated neurofilament light chain (NfL) concentrations as a highly sensitive biomarker for neuroaxonal damage along with cognitive performance during a course of ECT. Serum NfL concentrations from 15 patients with major depressive disorder receiving ECT were analyzed (1) 24 h before the first ECT, (2) 24 h and (3) 7 days after the last ECT (45 measurements in total). Neuropsychological testing including memory, executive functions and attention was performed at each time-point. NfL concentrations did not change between the three time-points, while a temporary cognitive impairment was found. Even in the subset of patients with the strongest impairment, NfL concentrations remained unchanged. Neuropsychological testing revealed the common pattern of transient cognitive side-effects with reduced performance 24 h post-ECT (global cognition score: p &lt; 0.001; memory: p = 0.043; executive functions: p = 0.002) and return to baseline after 7 days (all p &lt; 0.001). Our study adds to the evidence that neither ECT per se nor the transient cognitive side-effects seem to be associated with an increase of NfL as a marker of neuroaxonal damage. In contrast, we discuss cognitive side effects to be potentially interpreted as a byproduct of ECT's neuroplastic effects.</pubmed_abstract><journal>European archives of psychiatry and clinical neuroscience</journal><pagination>1187-1195</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11226499</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The myth of brain damage: no change of neurofilament light chain during transient cognitive side-effects of ECT.</pubmed_title><pmcid>PMC11226499</pmcid><pubmed_authors>Besse M</pubmed_authors><pubmed_authors>Wiltfang J</pubmed_authors><pubmed_authors>Zilles-Wegner D</pubmed_authors><pubmed_authors>Belz M</pubmed_authors><pubmed_authors>Bartels C</pubmed_authors><pubmed_authors>Herzig B</pubmed_authors></additional><is_claimable>false</is_claimable><name>The myth of brain damage: no change of neurofilament light chain during transient cognitive side-effects of ECT.</name><description>Electroconvulsive therapy (ECT) is an effective, safe, and mostly well-tolerated treatment for patients with severe or difficult to treat depression or psychotic disorders. However, a relevant number of patients experience subjective and/or objective cognitive side-effects. The mechanism of these transient deficits is not yet clear. Thus, our study prospectively investigated neurofilament light chain (NfL) concentrations as a highly sensitive biomarker for neuroaxonal damage along with cognitive performance during a course of ECT. Serum NfL concentrations from 15 patients with major depressive disorder receiving ECT were analyzed (1) 24 h before the first ECT, (2) 24 h and (3) 7 days after the last ECT (45 measurements in total). Neuropsychological testing including memory, executive functions and attention was performed at each time-point. NfL concentrations did not change between the three time-points, while a temporary cognitive impairment was found. Even in the subset of patients with the strongest impairment, NfL concentrations remained unchanged. Neuropsychological testing revealed the common pattern of transient cognitive side-effects with reduced performance 24 h post-ECT (global cognition score: p &lt; 0.001; memory: p = 0.043; executive functions: p = 0.002) and return to baseline after 7 days (all p &lt; 0.001). Our study adds to the evidence that neither ECT per se nor the transient cognitive side-effects seem to be associated with an increase of NfL as a marker of neuroaxonal damage. In contrast, we discuss cognitive side effects to be potentially interpreted as a byproduct of ECT's neuroplastic effects.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Aug</publication><modification>2025-04-04T12:54:06.043Z</modification><creation>2025-04-04T12:54:06.043Z</creation></dates><accession>S-EPMC11226499</accession><cross_references><pubmed>37656172</pubmed><doi>10.1007/s00406-023-01686-8</doi></cross_references></HashMap>